Global Medical Device Podcast powered by Greenlight Guru

In this episode of the Global Medical Device Podcast, we’re joined by Elena Kyria, a talent acquisition specialist and CEO of Elemed. Elena delves into what it takes to climb the career ladder in the medtech industry, whether you're early or late in your career journey. Our host, Etienne Nichols, engages in a rich discussion on career paths, leveraging personal strengths, and the importance of networking and personal branding.Quotes"If you're not talking about the value that you add, how is anybody going to know what impact you're having?" - Elena Kyria"Everything's uncertain really, isn't it? What you've got to have is a clear sense of forwards and just have a goal." - Elena Kyria"Nobody goes to the gym and looks at the weights and gets fit. You have to do the reps." - Elena KyriaTakeawaysNetworking is Key: It's not just what you know, but who knows you and what they know you're doing.Visibility of Achievements: Share your successes within your company; if you don't, others may not recognize your contributions.Defining Success: Success doesn't always mean reaching the VP level; it's about personal satisfaction and contribution.Strengths and Weaknesses: Focus on your strengths but be aware of your weaknesses and compensate with your team.Career Paths: Understand the different career paths (leadership, expert, generalist) and what they entail for growth.Communication Skills: Strong communication skills are paramount for leadership and for translating technical details to a broader audience.Continuous Learning: Always seek new knowledge and experiences, no matter where you are in your career.Adaptability: Be prepared to pivot and adapt to changes within the industry and your career.Take Action: Don't just reflect on advice; apply it to make actual changes in your career approach.Reference Links:Elena Kyria's LinkedInElemedWorking GeniusGreenlight GuruEtienne Nichols' LinkedInRemember to engage with the hosts and guests on LinkedIn for feedback and further discussions. Don’t forget to leave a review on iTunes!*Interested in sponsoring an episode? Use this form and let us know!

This episode dives into the complex and often misunderstood MedTech market in China, featuring Elaine Tan, creator of MedTech Chopsticks, who translates the nation’s stringent regulatory language into actionable insights. Elaine and host Etienne Nichols discuss the substantial risks and rewards of bringing a medical device to China, highlighting the country's rapid execution, intense internal competition, and the shift from low-end manufacturing to a focus on high-level innovation. A key risk is that existing international certifications (like ISO and IEC) do not guarantee compliance, requiring local type testing and adherence to specific national standards.The conversation addresses how global medical device companies can structure their strategy amid ongoing geopolitical shifts and the "China for China" policy, which favors domestic products through initiatives like the Volume-Based Procurement (VBP). Strategies such as the dual-strategy approach—localizing low-consumable manufacturing while protecting high-technology IP through joint ventures or careful CMO/CDMO selection—are explored as pragmatic ways to secure market presence and margin. Understanding the regulatory landscape, particularly the NMPA's 2021 overhaul, is crucial for success.Finally, Elaine provides practical guidance for regulatory professionals intimidated by the market. This includes understanding the specific regulatory and clinical pathways, performing a gap analysis against Chinese standards (Product Technical Requirements or PTR), and the critical process of selecting and qualifying a local partner/agent. Elaine reveals a specific, often overlooked hurdle: the agent must possess an NMPA-approved CA (Certification Authorization) USB key to electronically submit registration files on behalf of the foreign manufacturer, a critical piece of the submission puzzle. The discussion also touches on leveraging special zones, like the Hainan Free Trade Zone, for crucial real-world data collection applicable to the Chinese population.Key Timestamps[02:40] Introduction to Elaine Tan, MedTech Chopsticks, and the show’s focus on the China market.[05:05] High-level risks and rewards: complexity, lengthy registration, local testing requirements, and IP concerns.[08:08] Discussing the NMPA's 2021 regulatory overhaul and the geopolitical shift toward "China for China."[11:00] The Dual Strategy approach: balancing low-end localization with protecting high-tech IP.[14:48] Using CDMOs/CMOs for pilot projects to manage financial investment risk.[16:20] Leveraging the Hainan Free Trade Zone (Bo’ao region) for pre-market clinical data collection and urgent needs product access.[18:42] Ethological differences and their impact on clinical data justification (e.g., Pulse Oximeters).[20:17] NMPA predicate search: The importance of using the Chinese Classification Catalog to find registered, local predicate devices.[23:00] Guidance for overwhelmed regulatory professionals entering the China market: Clinical strategy and Product Technical Requirements (PTR).[25:52] Pitfalls in partner selection: The necessity of the NMPA-approved CA (Certification Authorization) USB key for submissions.[29:30] Partner qualification: Ensuring the agent can support Post-Market Surveillance (PMS) and QMS self-inspection requirements.[30:52] Final pitfall: International compliance (ISO/IEC) does not automatically ensure China compliance.Quotes"The requirements that you have fulfilled in the earlier stages might not be sufficient to enter market. They need to have local testing [and] need to compliant with the local standard." - Elaine Tan"For China, NMPA would like to actually emphasize that you need to select a predicate which has been approved in China markets already... This product have to be already registered to be valid and to be applicable to be used as a predicate device." - Elaine TanTakeawaysMandatory Localization is Key: Be aware that high international compliance (ISO, IEC) does not substitute for mandatory local type testing and adherence to China's specific Product Technical Requirements (PTR). Factor this into your R&D and budget early on.Employ a Dual-Strategy for IP: For high-tech, innovative products, avoid placing core IP entirely within China. Consider a hybrid structure using joint ventures, strategic CMO/CDMO partnerships, or utilizing international patents to safeguard your know-how while localizing the manufacturing of less innovative consumables.Leverage Special Pathways: Explore regional initiatives like the Hainan Free Trade Zone (Bo’ao region). This area allows for early, pre-market clinical collaborations to collect essential real-world data on the Chinese population, which is often required to justify clinical significance based on ethological differences (differences based on race/demographic).Vet Your China Agent Rigorously: The most critical qualification for your foreign regulatory agent is not just experience, but their possession of the NMPA-issued CA (Certification Authorization) USB key. Without this physical credential, they cannot electronically submit your registration files.Understand NMPA Predicate Rules: When developing your clinical strategy, the NMPA requires the selection of a predicate device that is already approved and registered in the Chinese market, regardless of whether it is domestic or foreign-made. Use the NMPA Classification Catalog to find the correct "common name" to search their database effectively.References:NMPA (National Medical Products Administration): The regulatory authority in China responsible for medical device approvals and oversight.Product Technical Requirements (PTR): A key NMPA requirement document defining the specific performance, testing, and compliance standards for a medical device in China.Hainan Free Trade Zone (Bo'ao region): A special economic and medical tourism zone that permits the use of certain internationally approved, urgently needed medical devices before formal NMPA registration, allowing for local clinical data collection.Elaine Tan's LinkedInEtienne Nichols' LinkedIn: Connect with EtienneMedTech 101 SectionEthological Differences: In the context of medical devices and clinical trials, "ethological differences" refers to the variations in biological, anatomical, or physiological characteristics between different human races or demographic populations. A classic example is a pulse oximeter: because the device measures oxygen saturation based on light absorption in the blood, the different skin tones across populations can affect the light's absorption rate. Therefore, data collected only on one demographic may be insufficient to prove clinical safety and efficacy in another, requiring local testing for products sensitive to these population differences.CA (Certification Authorization) USB Key: This is a crucial physical piece of hardware, similar to a security token, issued by the NMPA to accredited foreign manufacturer agents. It functions as a unique digital signature and login credential, which must be plugged into a computer for the agent to access the NMPA's electronic platform and successfully submit all regulatory and registration documents. Its possession is non-negotiable for an agent handling foreign medical device registrations.Feedback Call-to-ActionWe want to hear from you! Your feedback is invaluable in shaping the future of the Global Medical Device Podcast. Did this discussion help clarify your strategy for the Chinese market? Do you have experience with the NMPA's CA key or the Hainan Free Trade Zone? Send your comments, feedback, or suggestions for future topics directly to podcast@greenlight.guru. We emphasize personalized responses, so reach out—we’d love to hear your insights.SponsorsThis episode is brought to you by Greenlight Guru, the only MedTech-specific platform providing both QMS (Quality Management System) and EDC (Electronic Data Capture) solutions. Navigating the regulatory complexities of the Chinese market, including meeting the rigorous Product Technical Requirements (PTR) and managing extensive documentation, demands a specialized system. Greenlight Guru's platform is designed to streamline compliance for multiple global markets, ensuring you have a secure and compliant foundation for your device’s entire lifecycle, whether you're dealing with local type testing or post-market surveillance audits.

This "Meet the Guru" episode introduces Alex Naber, a seasoned medical device consultant at Greenlight Guru, offering listeners a deep dive into his background and expertise. Alex shares his journey, beginning in bioengineering and progressing through roles in complaints, field action, design quality, and post-market quality management at a major orthopedic company (Zimmer Biomet). His experience highlights the crucial need for expert guidance in navigating complex MedTech regulations and quality management system (QMS) pathways.Alex and host Etienne Nichols discuss the immense value of having a diverse internal team of consultants to draw from—a collective knowledge base that helps solve complex problems for clients. They emphasize that quality professionals don't need to know "everything" but rather must have the right resources and a "beginner's mindset" to guide companies effectively. The conversation also explores how modern software, like Greenlight Guru's QMS and EDC solutions, eliminates common industry pain points, such as fragmented, error-prone spreadsheet-based design controls by building true, linked traceability directly into the eQMS.Finally, the discussion touches on the philosophical "why" of the medical device industry: the patient. Alex shares a personal story about how orthopedics improved his grandfather's quality of life, underscoring the importance of maintaining a patient-first ethos. They conclude by discussing the upcoming QMSR transition, reassuring listeners that compliance is manageable, especially for those already adhering to ISO 13485.Key Timestamps[01:50] Alex Naber's MedTech Career Path: From Bioengineering to Design Quality and Post-Market Management.[04:30] The Power of Pooled Expertise: Why Greenlight Guru's Consultant Team is a "Sherpa up the mountain."[07:35] The Problem with Spreadsheets: Comparing traditional Design Control methods to modern eQMS traceability.[11:00] Accelerating Compliance: How Greenlight Guru's QMS Templates dramatically cut implementation time.[13:30] The Bloated QMS: Why adopting procedures from large corporations may hinder small-to-midsize companies.[16:00] Design Quality Explained: Marrying R&D/Product Development with QMS compliance.[21:30] The MedTech Ethos: Focusing on the patient and improving quality of life.[27:00] CAPA Management Insights: The critical distinction between Correction and Corrective Action.[30:25] Navigating the QMSR Transition: Reassurance that compliance isn't "that deep" if you are already ISO 13485 compliant.Quotes"It's a rewarding thing to just understand that you don't need to know everything. I think that's a thing that... people should realize and they should reach out to other people that are smarter or more experienced in realms that they don't understand." - Alex Naber"I think what got me into MedTech was more of the ethos behind it... We're creating products to make patients' lives better, to impact our world, our society in a positive manner, to give a better quality of life to individuals." - Alex NaberTakeawaysSeek a Unified Quality Solution: Fragmented quality processes (e.g., design controls in spreadsheets separate from the QMS) introduce significant regulatory risk. Adopting an eQMS, like the Greenlight Guru QMS solution, creates true traceability and dramatically streamlines compliance.Design Quality as a Partner, Not Police: Design Quality Engineers should actively partner with R&D, not just enforce rules. This involves educating product development teams on the why behind documentation and regulations to collaboratively find compliant solutions.Implement CAPA Early and Correctly: A robust CAPA process is essential long before market entry. Quality professionals must know the difference between a correction (fixing the immediate issue) and a corrective action (addressing the root cause) to prevent systemic non-conformances.Leverage QMS Templates for Speed: For new or growing companies, utilizing pre-validated QMS templates, like those offered by Greenlight Guru, can cut months off the time required to establish a 13485 or FDA CFR Part 820/EU MDR compliant system.QMSR is Not Overwhelming: As the QSR evolves into the Quality Management System Regulation (QMSR), companies already adhering to ISO 13485 will find the transition is relatively minor, primarily requiring minor updates rather than a complete overhaul of their existing QMS.ReferencesAlex Naber's LinkedInEtienne Nichols' LinkedIn: Connect with EtienneISO 13485:2016: The international standard specifying requirements for a quality management system where an organization needs to demonstrate its ability to provide medical devices and related services that consistently meet customer and applicable regulatory requirements. Relevance: This is the foundation for managing QMS changes, including the QMSR transition.Quality Management System Regulation (QMSR): The upcoming modernization of the FDA’s Quality System Regulation (21 CFR Part 820), harmonizing U.S. requirements with ISO 13485. Relevance: The central regulatory change discussed at the end of the episode.MedTech 101 SectionDesign Quality: In the medical device industry, Design Quality (DQ) is a specialized function within the Quality Assurance (QA) department. Its role is to ensure that the process used to design and develop a new medical device is compliant with the company's QMS procedures and applicable regulations (like FDA 21 CFR Part 820 or ISO 13485). Think of Design Quality as the engineer's compass and map for compliance—they guide the R&D team to make sure every requirement, test, and risk mitigation is properly documented and linked, preventing costly issues down the line. Without DQ, R&D teams might build a great product that can't be legally sold.Correction vs. Corrective Action: These two terms are often confused in quality management:Correction: The immediate action taken to fix a non-conforming issue. Example: A batch of surgical instruments has burrs, so the correction is to re-polish them.Corrective Action (CAPA): A deeper, systemic action taken to eliminate the root cause of a non-conformance so it does not happen again. Example: The corrective action is revising the manufacturing work instruction to include mandatory daily calibration of the machine causing the burrs.Feedback Call-to-ActionWe want to be your trusted voice in MedTech! We are committed to providing the most useful, actionable insider knowledge in the industry. Please help us by sharing your thoughts on this episode, suggesting future topics, or leaving a personalized review on your favorite podcast platform.Send your feedback, topic ideas, and questions directly to podcast@greenlight.guru. We personally read every email and truly value your input.SponsorsThis episode of the Global Medical Device Podcast is brought to you by Greenlight Guru, the only MedTech-specific platform that provides both a powerful Quality Management System (QMS) and industry-leading Electronic Data Capture (EDC) solutions. Alex Naber, an expert consultant from Greenlight Guru, highlights in this episode how integrating your design controls—the subject of his design quality expertise—directly into a compliant eQMS is the key to accelerating product development, eliminating audit anxiety, and truly improving the quality of life for patients. To learn more about how Greenlight Guru's dedicated solutions can streamline your path to market, visit www.greenlight.guru.

In this episode, host Etienne Nichols and guest Dr. Allison Komiyama, CEO and Founder of Blue Stocking Health, dive into a fascinating dialogue about the language used in healthcare and MedTech, particularly the terms patient, customer, and user. They explore how these words influence the perception of care, service, and the entire medical device development process. The conversation touches on the friction and inefficiencies that arise when the relationship dynamic is unclear, highlighting the different nuances between passively receiving treatment and being an active consumer of health services.The discussion delves into the historical context of the word "patient," which is rooted in the Latin patior, meaning 'to suffer.' Dr. Komiyama shares insights from industry conferences, noting that many individuals prefer to be called a "person" or an "empowered patient" rather than a passive sufferer. This ties directly into the growing movement of individuals seeking to own their health and be active participants in their care, fueled by readily available information and a focus on health span over just disease treatment.Ultimately, the key takeaway for MedTech innovators is the importance of understanding their end-user and tailoring their language—in labeling, clinical studies, and human factors testing—to align with the user's preferred terminology. The shift from "caregiver" to "care partner" is highlighted as a prime example of evolving language that acknowledges a collaborative, mutual relationship, moving away from a hierarchical structure to one of shared purpose.Key Timestamps[0:01:25] - Introduction to Dr. Allison Komiyama and Blue Stocking Health's mission to amplify the good of MedTech.[0:04:14] - Discussion begins: Patient vs. Customer vs. User in MedTech.[0:06:05] - The etymology of "patient" (patior, to suffer) and the push for "person" or "empowered patient."[0:08:22] - Historical context: Passivity of the patient role and the doctor's assumed knowledge.[0:09:50] - The impact of consumerism, AI, and the "health span" movement on patient empowerment.[0:12:35] - The value of seeking multiple opinions and the role of patient priorities in customizing care.[0:15:30] - Shifting terminology: Why "caregiver" is moving toward "care partner."[0:18:22] - How language diversity enriches the conversation and enhances communication.[0:21:00] - Tying diverse language use to MedTech innovation and product development.[0:22:15] - The importance of understanding end-user biases and assumptions in MedTech.[0:24:25] - Impactful personal stories: How specific interactions define a positive care experience.[0:29:10] - Concluding thoughts: Why plurality and qualifiers (e.g., "empowered patient") may be the ideal goal.Quotes"I think there's a lot of folks at FDA even that we're like, we don't want to use the word patient. We want to use the word person. And patient actually comes from the term patior, which means to suffer." - Dr. Allison KomiyamaTakeawaysRegulatory & Clinical Strategy: When defining the target population for your device—in 510k, IDE, or PMA submissions—be mindful of the terminology. Consider using terms like "end-user," "person living with [condition]," or "care partner" alongside "patient" to reflect a modern, inclusive understanding of the device's human context.Human Factors & Usability: Language directly impacts product use. As an R&D or Human Factors professional, align your labeling and instructions with the language that resonates most with your defined user group. Utilizing terms like "care partner" for non-professional support ensures that instructions for use are mutually supportive and not hierarchical.Marketing & Communication: MedTech companies should audit their external communications, including advertisements and white papers. A focus on "customer service" aspects (efficiency, speed, clear communication) can resonate more with the consumer/customer mindset than traditional "patient" messaging, provided it is balanced with clinical integrity.Quality Management Systems (QMS) & Design Input: Use diverse language during design input collection to capture a broader range of needs. Focus groups that employ words like "user experience" and "customer journey" often uncover different, yet equally critical, insights compared to those solely focused on "patient safety" and "treatment protocol." Greenlight Guru's QMS and EDC solutions help capture and manage these diverse inputs effectively, ensuring alignment with both clinical and user needs.Professional Dialogue: Embrace "strong opinions held loosely." MedTech leaders should cultivate internal and external dialogues that challenge existing assumptions about user terminology. A willingness to be corrected is key to identifying blind spots in product development and market strategy.ReferencesDr. Allison Komiyama's LinkedInEtienne Nichols' LinkedIn: Connect with EtienneBlue Stocking Health: A company dedicated to redefining and amplifying the conversation around medical technologies.The Media Bias Chart / Ad Fontes Media (Vanessa Otero): Mentioned in the episode as an example of thoughtful dialogue and understanding different perspectives.MedTech 101 SectionCaregiver vs. Care PartnerIn the MedTech and healthcare world, the distinction between Caregiver and Care Partner is an important example of evolving language.Caregiver: Traditionally, this term suggests a one-way, hierarchical relationship where one person provides care and the other passively receives it. It often implies a professional role or a person solely responsible for the physical needs of another.Care Partner: This term signifies a mutual, collaborative relationship. It acknowledges that the person with the health condition is an active participant in their own care and that their support person (spouse, family member, friend) is working alongside them to manage the condition. It's a key linguistic shift that promotes empowerment and shared decision-making.Analogy: Think of a dance. A Caregiver might be seen as the instructor directing every move, while a Care Partner is an equal on the dance floor, moving together with shared goals and rhythm.Feedback Call-to-ActionWe want to hear from you! Do you prefer to be called a patient, a customer, or a partner in your health journey? Your feedback drives our content and helps us bring the most relevant topics to the MedTech industry. Send your thoughts, episode reviews, and topic suggestions directly to us at podcast@greenlight.guru. We read every email and aim to offer personalized responses.SponsorsThis episode of the Global Medical Device Podcast is brought to you by Greenlight Guru. In a complex and evolving industry, managing your processes efficiently is critical. Greenlight Guru provides the industry's leading suite of solutions: a Medical Device QMS to simplify compliance and accelerate product development, and Clinical Data Solutions (EDC) to streamline and digitize your clinical trials. The ability to embrace a user-centric approach, whether you call them a patient or a customer, requires robust quality and clinical data infrastructure—precisely what Greenlight Guru delivers. Learn how their solutions can power your next-generation medical device innovation.

This episode, hosted by Etienne Nichols, delves into the critical impact of a U.S. government shutdown on the medical device industry, specifically focusing on the Food and Drug Administration (FDA). Guest Michael Nilo, President and Principal Consultant of Nilo Medical Consulting Group and a former FDA Scientific Reviewer, offers an insider's perspective on which FDA functions halt and which remain active during a funding lapse. He clarifies that while the processing of new, user-fee-supported marketing applications like PMAs and 510(k)s typically stops, essential activities like active review of already-filed submissions, post-market safety surveillance, enforcement of recalls, and Investigational Device Exemption (IDE) reviews continue, drawing on existing user fee reserves.The discussion pivots to the significant slowdowns that occur, notably the suspension of non-MDUFA-goal-tied interactions, such as Q-submissions (Pre-Submissions) and most interactive reviews. For startups and small manufacturers, the halting of the crucial small business designation processing can be particularly detrimental, leading to astronomically higher user fees once the government reopens. Michael emphasizes that the industry should anticipate this political risk and plan submission timelines strategically, positioning a government shutdown as an "uncontrollable natural disaster" that requires proactive risk mitigation.Michael provides actionable advice for MedTech leaders to pivot during a shutdown. He recommends using the enforced delay to significantly improve the quality of submissions—making them easier to navigate and review once the FDA is fully operational—to gain a crucial advantage over the backlog of queued submissions. Furthermore, companies should utilize the time to focus on parallel activities such as process validation, refining quality systems, and strengthening commercial and reimbursement strategies. Michael stresses the importance of remembering the core mission: getting life-improving technologies to patients, and using any delay as an opportunity to emerge stronger and more prepared for commercial launch.Key Timestamps1:45 - The initial effects of a shutdown: What truly stops at the FDA (new submissions) versus what keeps running (existing reviews, IDEs, post-market surveillance).3:50 - Why active review of filed submissions continues—the role of the user fee "reserve."5:58 - Critical functions that stop or slow down: Pre-submissions (Q-subs), interactive reviews, new policy guidance, and routine inspections.7:25 - The major impact of halting the small business designation process on user fees for new manufacturers.8:36 - MDUFA (Medical Device User Fee Amendments) explained: How user fees fund the FDA and maintain operations during a lapse.11:51 - Direct effects on a MedTech company's runway and the loss of interactive review.13:17 - Actionable advice: Improving submission quality for easier review to mitigate the post-shutdown backlog.15:00 - Strategic pivot: Focusing on parallel work like process validation and quality system refinement.16:03 - Communicating with investors and partners: Positioning the shutdown as an uncontrollable event and shortening the commercial launch gap.18:50 - Looking ahead: Planning submissions around budget resolution deadlines to anticipate shutdown risk.20:53 - Final advice: Keeping the patient-focused mission in mind and maximizing internal efforts.Quotes"Active review of device submissions, if you already had something in or you were smart enough, you saw the writing on the wall, you got it in on September 30, you’re good to go. Those will still keep going on schedule with and the FDA is going to try to meet their MDUFA goals..." - Michael Nilo"If yours stands out as being something that is easier to handle, makes it easier to process, they can navigate through it better, you have a better chance of getting a quicker, faster, better review process once it’s opened up."TakeawaysRegulatory Strategy & Submission Quality: Use any government shutdown delay to drastically improve the navigability and clarity of your marketing submission (PMA, 510(k)). A well-organized, hyperlinked, and clear application will likely be processed faster by reviewers facing a post-shutdown submission backlog.Financial Risk & Small Business Designation: Small medical device manufacturers should anticipate potential government shutdowns and file their small business designation application well in advance. Failure to process this designation during a lapse can result in paying the full, significantly higher user fee, which dramatically impacts startup runway.Operations & Quality Focus: While regulatory submissions are stalled, pivot R&D and Quality teams to focus on parallel work streams. This includes advancing process validation, completing outstanding quality system activities (e.g., risk management file updates), and solidifying commercialization and reimbursement strategies.IDE Reviews Continue: Companies initiating clinical trials should note that Investigational Device Exemption (IDE) submissions are generally considered essential and will still be reviewed within the MDUFA 30-day timeline. This is one of the few submission types that allows for continued progress during a shutdown.Leverage User Fee Systems: Understand that the FDA's user fee structure (MDUFA) ensures that key pre- and post-market safety functions, as well as active review of existing applications, can be maintained for a period, acting as a crucial shock absorber for the industry.ReferencesMichael Nilo's LinkedInEtienne Nichols' LinkedIn: Connect with EtienneMDUFA (Medical Device User Fee Amendments): The legislation that authorizes the FDA to collect fees from companies that submit certain marketing applications for medical devices, which funds a significant portion of the agency's device-related activities and performance goals.IDE (Investigational Device Exemption): An FDA process that allows a device that is not yet legally marketed to be used in a clinical study to collect safety and effectiveness data. IDE reviews are generally protected during a shutdown.MedTech 101 Section: User Fees and the MDUFA BufferWhen the U.S. government shuts down, it means Congress hasn't passed a budget, and non-essential federal agencies must pause most operations because their taxpayer funding stops. However, the FDA has a financial safety net for its medical device work: User Fees, authorized by the Medical Device User Fee Amendments (MDUFA).Think of MDUFA as a dedicated savings account funded by MedTech companies. When a company submits a major application like a 510(k) or PMA, they pay a fee. This money goes into a separate reserve. When a government shutdown happens, the FDA can tap into this reserve to keep essential, MDUFA-related work going. This includes the salaries of reviewers who are already working on your application, ongoing post-market surveillance, and crucial safety functions. The money acts as a buffer, allowing the FDA to continue its core mission for a limited time, which is why existing reviews aren't immediately halted. New submissions, however, often can't be processed because that intake and processing function is deemed non-essential and is not typically covered by the emergency user fee funding.Feedback Call-to-ActionWe thrive on your input! If this discussion about government shutdowns and MedTech strategy sparked any thoughts, or if you have a topic you'd like us to cover, we want to hear from you. Email us directly at podcast@greenlight.guru. We personally read every email and are committed to providing you with the most relevant and actionable MedTech insights.SponsorsThis episode is brought to you by Greenlight Guru, the only MedTech-specific platform providing end-to-end solutions. Don't let a government shutdown pause your internal quality momentum. Leverage Greenlight Guru's eQMS and EDC solutions to keep your product development, design controls, and clinical data management moving forward, ensuring your systems are inspection-ready and helping you build a submission so flawless it cuts through the FDA's post-shutdown backlog. Visit www.greenlight.guru to learn more.

This episode of the Global Medical Device Podcast, hosted by Etienne Nichols with guest Shannon Decker, CEO of VBC1 and an expert in healthcare transformation, dives deep into the science of how adults learn, contrasting pedagogy (child-centered learning) with andragogy (adult-centered learning). The discussion reveals why traditional training methods, like handing new hires 40 SOPs to read, are often ineffective for experienced professionals in the MedTech industry.Shannon explains the core principles of andragogy: adults are self-directed, problem-centered, and bring a vast reservoir of experience to the table (schema theory). They are less motivated by sequential, externally guided learning and more by what is relevant, timely, and what is in it for them. This self-directed approach means successful training in MedTech requires catering to intrinsic motivation and providing tactile, real-world practice rather than just videos or documentation.The conversation pivots to practical applications across the medical device lifecycle. Shannon shares compelling examples, like improving physician adoption of a medical device by shifting the focus from extrinsic financial rewards and regulatory compliance to the intrinsic motivation of improving patient health outcomes. By making users part of the development process and using performance feedback to tap into a professional's competitive spirit, organizations can achieve significantly higher engagement and successful adoption of new technologies.Key Timestamps[03:20] What is Andragogy? How adults learn differently than children.[04:45] The role of schema theory and existing experience in adult learning.[05:40] Why the traditional "drop 40 SOPs" on a new hire’s desk fails adults.[07:15] Case Study: The challenge of low medical device adoption and the missing education piece.[08:50] The power of tactile practice and addressing user confidence (e.g., misusing the device).[11:00] Contrasting Andragogy (self-directed) vs. Pedagogy (directed/sequential).[14:10] Applying adult learning to device development: solving the user's problem.[16:45] How to boost adoption: Intrinsic motivation and making users part of the process.[18:20] The key physician motivator: Desire to help people over money or administrative requirements.[21:10] Behavior science: Focusing on influential champions and mid/top performers for diffusion.[22:45] The "Gold Star" effect: Using competitive spirit and relevant KPIs for motivation.Quotes"The way we come to learning with adults is different... The best way that they learn is coming up with things that are relevant to them, things that are timely, things that they need. They want to be interested." - Shannon Decker"I don't talk about the money that they're going to make... What I talk to them about is by paying attention and doing these screening exams, you're going to have an impact on the overall health of your patient." - Shannon DeckerTakeawaysStop Relying on Documentation for Training: Adult learners need tactile input and practice. Replace or supplement large volumes of SOP reading with project team involvement, practical exercises, and hands-on use to build confidence and retention.Focus on the "What's In It For Me" (WIIFM): When designing a medical device or a training program, identify the user’s intrinsic motivations. For clinicians, this is often the desire to improve patient outcomes—lead with this message rather than revenue or regulatory burden.Build Champions, Not Just Compliance: Instead of solely focusing energy on low performers or the loudest voices, identify respected, influential leaders (champions) to pilot and advocate for new technology. Their positive experience drives the Law of Respect and encourages wider adoption.Use Performance Data as a Motivator: Feedback and benchmarking can tap into a professional’s competitive spirit. Monitor device usage and provide timely, relevant feedback (the "Gold Star" effect) using KPIs that matter to their professional values, not just revenue goals.Make Users Part of the Process: Involve clinicians and end-users in the development cycle early on. Actively listening to their challenges and integrating their feedback ensures the final product is designed to solve their problems and fits seamlessly into their existing workflow.ReferencesDr. Shannon Decker's LinkedInEtienne Nichols' LinkedIn: Connect with EtienneSchema Theory: Discussed as the framework for how adults integrate new information with their existing base of knowledge and experience.MedTech 101 Section: Pedagogy vs. AndragogyPedagogy and Andragogy are two core concepts in education theory that explain how different groups of people learn.Pedagogy (Child Learning): This is the traditional model where the teacher is in charge. Learning is directed, sequential, and structured by an authority figure (e.g., a child must learn A before they learn B). The child relies on the teacher for direction and motivation.Andragogy (Adult Learning): This model recognizes that adults are fundamentally different learners. Adult learning is self-directed, problem-centered, and motivated by relevance. Adults must understand why they need to know something and how it immediately applies to their lives or work. They also leverage their deep existing experience base (their schema) to evaluate new information.Why it matters in MedTech: In a fast-paced field like medical devices, requiring an engineer to passively read 40 procedural documents (a pedagogical approach) is inefficient. Using an andragogical approach—by giving the engineer a project, showing them how the procedure solves a real-world problem, and having them practice the task—results in faster adoption, greater compliance, and better performance.Feedback Call-to-ActionWe want to hear from you! Do you use andragogy principles in your training? Have a question about leveraging intrinsic motivation in your team?Send your feedback, episode reviews, or topic suggestions directly to the Podcast Producer: podcast@greenlight.guru. We read every email and your input helps shape the future of the Global Medical Device Podcast.SponsorsThis episode is brought to you by Greenlight Guru, the only MedTech-specific platform with both a next-generation QMS and an integrated Electronic Data Capture (EDC) solution.In an industry where successful training and adoption rely on integrating quality with practical use, Greenlight Guru helps you eliminate disconnected, clunky systems. By integrating your quality processes (QMS) with your clinical data capture (EDC), you ensure your teams are operating on the same source of truth, making it easier for adult learners—from R&D to clinical investigators—to understand and adopt your technology. Get the purpose-built platform that helps you design and build higher quality devices faster. Learn more at greenlight.guru.

This episode tackles the often-overlooked but critical topic of medical device reimbursement. Host Etienne Nichols speaks with Haley King, co-founder and CEO of Paxos Health, about why this process is just as vital as FDA approval for a device's commercial success. They explore the journey a medical device takes, highlighting the distinction between FDA approval and securing reimbursement from payers.Haley explains the three key pillars of reimbursement: coding, coverage, and payment. She delves into the complexities of CPT codes and the significant difference between a temporary Category 3 code and the gold-standard Category 1. The discussion also covers the immense challenges medical device companies face, including the lengthy timeline—sometimes years—to secure payer coverage, which can be a make-or-break factor for startups. The conversation wraps up with a look at how artificial intelligence is beginning to streamline the cumbersome, manual process of patient access and appeals.Key Timestamps1:45 - The initial challenge of making coverage match medical need.3:30 - The three-part reimbursement pathway: coding, coverage, and payment.5:50 - Navigating CPT codes and the difference between Category 1 and Category 3.10:15 - Common challenges for medical device companies seeking payer coverage.13:20 - The multi-year timeline to achieve Medicare coverage for innovative devices.15:00 - Advice for regulatory and quality professionals on speeding up reimbursement.20:10 - How AI is currently being used in patient access and reimbursement.24:45 - Debating the accuracy of AI and its role in replacing human expertise.Quotes"A lot of times patients are not going to be able to pay out of pocket for expensive medical treatments, and a lot of times providers are not going to be able to write off those treatments on their side. So somebody needs to pay for this. And that's usually the health insurance companies..." — Haley King"I think that for this sort of a use case [AI], you're always going to want some human in the loop... AI has the potential to be super, super powerful in this space, but I think you're always going to want to have human experts involved." — Haley KingTakeawaysIntegrate reimbursement strategy early: Unlike FDA approval, which focuses on safety and efficacy, payers also demand evidence of a device's clinical and economic value. Medical device companies, particularly startups, should integrate reimbursement planning into their pitch decks and product development timelines from the outset.Recognize the two-step process: FDA approval is not a golden ticket to reimbursement. Companies must understand the subsequent and often lengthy process of securing coding, coverage, and payment from payers like CMS and private insurance companies, which can take several years.Enhance clinical trials for payers: Regulatory and quality professionals can speed up the reimbursement process by designing clinical trials that not only meet FDA requirements but also generate robust data to prove a device's clinical and economic value. This may involve including additional endpoints to justify the cost.Harness AI for efficiency, not replacement: AI is a powerful tool for automating the tedious parts of reimbursement, such as sifting through patient records and payer policies. However, it should be viewed as a way to enhance, not replace, the work of human experts who can handle complex edge cases and appeals.Be aware of coding complexities: The distinction between a temporary Category 3 CPT code and a permanent Category 1 code is a major hurdle for innovative devices. Companies must be prepared for a potential multi-year journey to prove their device’s value to the American Medical Association (AMA) and payers.ReferencesPaxos Health: Haley King’s company, which helps patients and physicians navigate insurance barriers for medical care.Current Procedural Terminology (CPT) Codes: The standardized language used by healthcare providers and payers to bill for medical services.Study on Payer Coverage: A 2023 study referenced in the episode, with authors including Josh Macaur and Dr. Erin Saxton, that found a nominal time of 5.7 years for innovative medical devices to achieve Medicare coverage.You can also connect with Global Medical Device Podcast host Etienne Nichols on LinkedIn: https://www.linkedin.com/in/etienne-nichols-824a7114/MedTech 101: The CPT Code BreakdownThink of a CPT (Current Procedural Terminology) Code as a unique ID number for a specific medical procedure or service. When a doctor performs a treatment, they use this code to communicate with an insurance company (payer) what they did so they can get paid.Category 1 Codes are like the established, official ID numbers. They're for widely accepted procedures with proven clinical value and are typically covered by insurance.Category 3 Codes are like temporary ID numbers. They are assigned to newer, innovative procedures that are still being studied. They allow doctors to track the procedure's use, but they don't guarantee that insurance will pay for it. The goal is to collect enough data over time to upgrade to a Category 1 code.Feedback Call-to-ActionYour feedback helps us create content that matters to you. Have a topic suggestion or a question about this episode? Please reach out to us at podcast@greenlight.guru. We read every email and appreciate your insights!SponsorsThis episode is brought to you by Greenlight Guru, the only medical device success platform built specifically for MedTech companies. As discussed in this episode, getting your device to market requires more than just a great product; it needs a robust quality system and a clear path to market adoption. Greenlight Guru's QMS and EDC solutions are designed to streamline your development process from concept to commercialization, helping you secure the data needed for both FDA approval and payer reimbursement. To learn more, visit www.greenlight.guru.

In this episode, host Etienne Nichols sits down with Jose Bohorquez and Mohamad Foustok from CyberMed to dissect the complex world of Software as a Medical Device (SaMD) and cybersecurity. They emphasize that SaMD is first and foremost a medical device and should be treated as such from the very beginning of the development process. The conversation highlights the most common mistakes companies make, like treating security as an afterthought and jumping straight into coding without a solid architectural plan.Mohamad Foustok introduces the concept of "zero trust" and the critical importance of designing for security across the entire product lifecycle, from initial concept to post-market surveillance. The discussion clarifies that cybersecurity is not limited to network-connected devices but applies to any medical device with a software function, regardless of its connectivity. They also touch on the historical context of FDA guidance, noting a significant shift in recent years that has raised the regulatory bar and put a greater emphasis on robust cybersecurity documentation.The guests provide actionable advice for MedTech professionals, stressing the value of a balanced approach that integrates security and functionality from day one. They explain that a well-thought-out process, though seemingly slower at the outset, ultimately saves time and resources by preventing costly and time-consuming redesigns later on. This episode serves as a vital guide for anyone looking to build a secure and compliant medical device in today's evolving regulatory landscape.Key Timestamps[01:50] Common pitfalls in developing SaMD, including overlooking regulatory guidance like IEC 62304.[03:20] The critical mistake of treating cybersecurity as an afterthought in product development.[05:00] Who cybersecurity applies to beyond software, including patients, manufacturers, and supply chains.[06:30] The FDA's stance on cybersecurity for any device with a software function, even if not network-connected.[08:00] A discussion on "reasonable assurance of cybersecurity" and what it means for manufacturers.[10:00] The "zero trust" principle and why you should never assume a network is secure.[14:00] How hospitals and other stakeholders are demanding more rigorous cybersecurity standards.[15:40] The ideal process for a "security-first" development lifecycle.[21:00] Why rushing development without a proper architecture can lead to significant delays and cost overruns.[23:00] A brief history of FDA's cybersecurity guidance and the major shift in 2023.Quotes"Software as a medical device ultimately is a medical device, and so you want to be developing it from the get-go with that mindset." — Jose Bohorquez"Security can't be an afterthought. You have to consider security at the inception of your approach to a product." — Mohamed FustokTakeawaysA "Security-First" Mindset is Essential: Integrate cybersecurity from the initial architectural phase of your project. This proactive approach saves significant time and money by avoiding costly redesigns and delays later in the development process or after an FDA submission.Cybersecurity is for All Software-Driven Devices: Don't assume that only cloud-connected devices need cybersecurity documentation. The FDA requires documentation for any device with a software function, including embedded systems and programmable logic, even if it's not connected to a network.Regulatory Compliance is a Process, Not a Document: The FDA is not just looking for a checklist of documents; they want to see a well-defined and consistently followed process for how you build and secure your software. This includes a "reasonable assurance of cybersecurity" that stands up to scrutiny.Hospitals are Your New Regulators: Beyond FDA compliance, be prepared for hospitals and other buyers to conduct their own rigorous cybersecurity audits. A strong cybersecurity posture is becoming a key differentiator and a prerequisite for market access.ReferencesIEC 62304: The international standard for medical device software life cycle processes. It is a foundational requirement for developing compliant medical software.FDA Guidance Documents: Specific documents from the U.S. Food and Drug Administration that provide detailed requirements for software as a medical device (SaMD) and cybersecurity.Etienne Nichols' LinkedIn: For more insights and connections in the medical device industry, connect with Etienne Nichols. [https://www.linkedin.com/in/etienne-nichols-105151241/]MedTech 101Zero Trust: A cybersecurity principle that means you should never automatically trust anything inside or outside of your network perimeter. Instead, every access request must be verified before granting access. Think of it like a strict security guard who checks everyone's ID, even if they claim to work there. In a hospital setting, this means a medical device should not assume the hospital's Wi-Fi is secure; it should treat every connection as potentially hostile and build in its own protections. This is in contrast to the old model where everything inside the network was trusted by default.Feedback Call-to-ActionWe love to hear from our listeners! Your feedback helps us create content that is most valuable to you. Please send your comments, topic suggestions, and guest recommendations to podcast@greenlight.guru. We read and respond to every email personally.SponsorsThis episode of the Global Medical Device Podcast is brought to you by Greenlight Guru. In a world where regulatory requirements for software are constantly changing, having a robust and agile Quality Management System is non-negotiable. Greenlight Guru's Medical Device QMS & EDC solutions are purpose-built to help you navigate these complexities, from initial design through post-market surveillance, ensuring your SaMD and other medical devices are secure, compliant, and ready for market. Visit their website to learn how their solutions can streamline your entire development process.

This episode with Stuart Grant of Archetype MedTech demystifies the "front end of innovation," a critical yet often overlooked phase of medical device development. Stuart, a seasoned MedTech veteran with over two decades of experience at Johnson & Johnson, shares insights from his doctoral research on this topic. He breaks down the process, defining the front end as the crucial period between applied science and new product development, where teams identify unmet clinical needs and shape a product concept. This conversation offers a clear roadmap for balancing creativity with structure, using the Design Council's Double Diamond model and Stuart’s 10 key insights for observing user behavior.Stuart Grant’s discussion on the front end of innovation highlights the importance of deeply understanding the user and the environment in which a device will be used. He introduces a number of tools and techniques, such as the Pugh Matrix and the NVivo software, to help teams transition from a broad exploration of ideas to a focused, viable product concept. Stuart explains that while the front end may seem "fuzzy," it can be a systematic process that uncovers the true clinical and market needs that will determine a product's success. He emphasizes that the most successful devices aren't just incrementally better, but are born from a deep understanding of customer insights.This episode is an essential guide for anyone involved in MedTech innovation, from academic researchers to seasoned engineers. Stuart's insights challenge the conventional reliance on key opinion leaders and provide a framework for a more holistic, user-centric approach. He outlines how to identify and interpret subtle user behaviors, from workarounds and unconventional uses to unspoken frustrations, all of which are critical for developing a truly impactful and user-friendly medical device. Whether you're at the very beginning of a project or looking to improve your current innovation process, this episode provides actionable strategies to bridge the gap between a great idea and a marketable product.Key Timestamps(2:00) Defining the "Front End": Stuart explains what the front end of innovation is and why its name has evolved from the "fuzzy front end."(8:00) The Double Diamond Model: An explanation of the UK Design Council's Double Diamond, illustrating the divergent and convergent phases of problem-solving.(12:30) Common Pitfalls: Discussing the three critical questions to answer: Is there a market (viability)? Is the technology possible (feasibility)? Do users want it (desirability)?(15:00) Balancing Creativity and Structure: The roles of different team members and how to manage the creative (divergent) and critical (convergent) phases of innovation.(21:00) 10 Ways to Find User Insights: Stuart breaks down the specific techniques and red flags to look for when observing users, including workarounds, affordances, and areas of disjuncture.(26:00) The Problem with KOLs: Why relying solely on key opinion leaders can be a mistake and the importance of observing a wider range of users.(30:00) Triggers of Use: How unconventional uses of a device can reveal new product opportunities.Standout Quotes"A craftsman will build you exactly what you ask for. An artist will build you what you didn't know you need." - Etienne Nichols"You don't just do what the customer says because that could lead to a terrible product." - Stuart GrantTakeawaysObservation is Key: Go beyond interviews. The most valuable insights come from observing users in their natural environment, such as a surgeon in the operating room. Pay attention to "workarounds" or unconventional uses, as these often reveal critical unmet needs.Balance Divergence and Convergence: Use a structured approach like the Design Council's Double Diamond to manage the innovation process. Start with a broad, creative phase to gather information and ideas (divergence), then narrow down and refine them into a concrete solution (convergence).Assemble a Diverse Team: The best innovation teams include a mix of skill sets, from engineers and designers to marketers and clinical representatives. Each function plays a critical role in controlling the process and ensuring the product is viable from multiple perspectives.Look for Disjuncture: Be on the lookout for inconsistencies between what a user says and what they actually do. This "disjuncture" can reveal hidden pain points and lead to profound insights that others might miss.Don't Over-Rely on KOLs: While key opinion leaders offer valuable expertise, their extensive experience can cause them to overlook usability issues that affect the majority of users. Include a diverse range of users in your research to ensure your product is accessible and effective for the broader market.ReferencesDesign Council Double Diamond: A visual representation of the design process, emphasizing phases of divergent and convergent thinking.Donald Norman, "The Design of Everyday Things": A foundational book on human-centered design, which discusses concepts like affordances.Pugh Matrix: A tool used to compare and evaluate multiple design concepts against a set of criteria.Etienne Nichols's LinkedIn ProfileMedTech 101: The Double DiamondImagine you have a new idea for a medical device. Where do you start? The Double Diamond model is a simple but powerful framework to guide you. Think of the first diamond as the "problem space." You start by diverging, or expanding your view, to explore every angle of a problem. This is like brainstorming—you collect a wide range of information about the user, the environment, and the clinical need without judgment. Then, you converge on a single, clear problem statement.The second diamond is the "solution space." You diverge again, this time to come up with many different ideas and concepts to solve the problem you've defined. You're thinking creatively about all the possible solutions. Finally, you converge one last time to select and refine the best solution, turning it into a concrete product concept. This process ensures you're not just solving a surface-level issue but a real, well-defined problem with a well-considered solution.Feedback Call-to-ActionWhat are your thoughts on the "front end" of innovation? Have you experienced any of the user insights Stuart discussed? We'd love to hear your stories and questions. Email us at podcast@greenlight.guru with your feedback or to suggest a topic for a future episode. We read every email and will respond to you personally.SponsorsThis episode is brought to you by Greenlight Guru, the only medical device success platform designed specifically for MedTech companies. Their MedTech Suite, including both QMS & EDC solutions, is built to address the unique challenges of medical device product development and quality management. Just as Stuart Grant highlighted the importance of a structured process to go from an idea to a marketable product, Greenlight Guru helps you manage that entire journey with purpose-built software. To learn how Greenlight Guru can help you navigate the entire product lifecycle, visit www.greenlight.guru.

In this episode, host Etienne Nichols sits down with seasoned MedTech entrepreneur Steve Bell to discuss the critical lessons for starting and scaling a medical device company. With over 30 years of global experience, Steve shares insights from his work with major corporations like Johnson & Johnson and his role in building Europe’s largest MedTech unicorn. He reveals how a conversation with his wife led him to develop an extensive course and a new MedTech AI tool to help founders navigate the complex and often unforgiving startup landscape.Steve emphasizes the importance of moving beyond a great idea to build a viable business. He outlines the foundational mistakes that sink over 75% of startups, from emotional attachment to non-viable concepts to underestimating the time and financial commitment required. He introduces his “greenhouse score” system, an objective, data-driven tool designed to help founders evaluate their business idea against global competition, urging them to "kill their ideas early" if they aren't built for success.The conversation also touches on the unique challenges facing first-time founders, including the critical decision of who should lead the company. Steve advises against a "have-a-go-hero" mentality and highlights the value of bringing in experienced leadership to avoid costly mistakes. He stresses that true success lies in being "needs-based, not product-based," focusing on solving a core problem rather than becoming overly attached to a specific solution. The episode concludes with a warning about protecting intellectual property (IP) and the costly mistake of sharing proprietary information prematurely.Key Timestamps00:02:13 The origin story of Steve's MedTech startup course.00:04:58 The #1 reason MedTech startups fail: A good idea isn't always a good business.00:08:54 The greenhouse score and MedTech AI advisor for objective business idea validation.00:11:09 Why entrepreneurship is a "wide open field" and how to find a path.00:12:00 The importance of "Location, Location, Location" for MedTech startups.00:13:58 The MedTech Survival Guide book and life lessons learned.00:17:02 Should a first-time founder be the CEO?00:18:10 How to find and compensate an experienced CEO.00:20:45 Why you must be needs-based, not product-based.00:22:47 The difference between a business and an orphan or philanthropic project.00:23:53 The risk of destroying your IP before you even get started.Quotes"Every idea is good, but not every idea is a good business... some of them are just really interesting tech that's trying to look for a home." - Steve Bell"Most likely thing for most companies is the idea you go in with is not the idea you come out with... You need to be needs-based, not product-based." - Steve BellTakeawaysValidate Your Idea Objectively: Don't rely on gut feelings. Use data-driven tools to assess your business idea's viability. If your "greenhouse score" is low, don't abandon the need—pivot the solution or fix the weaknesses.Stack the Deck in Your Favor: Simple, logical choices can significantly increase your odds of success. This includes selecting a strategic business location and prioritizing a strong team over a lone "have-a-go-hero" founder.Hire Experienced Leadership: A first-time founder should rarely be the CEO. Bringing in a seasoned professional with C-suite experience can save millions of dollars and years of development, as they bring invaluable scar tissue and a network of investors.Protect Your Intellectual Property: Be mindful of how you share information. Publishing abstracts or presenting data prematurely can destroy your ability to patent your invention. Treat your IP like a "billion-dollar map" and guard it accordingly.Focus on the "Need," Not the "Product": Your passion should be for solving a problem, not for a specific device. Your initial product idea may not be the one that succeeds, but your mission to solve the underlying clinical need should remain constant.ReferencesSteve Bell's MedTech Course: An extensive online course with over 100 videos designed to guide MedTech entrepreneurs from concept to exit.MedTech Advisor AI: An upcoming tool that uses an algorithm to provide an objective "greenhouse score" for MedTech business ideas.Greenlight Guru: Provides both a QMS and an EDC solution to help medical device companies of all sizes manage their product development and quality processes.Etienne Nichols' LinkedIn: https://www.linkedin.com/in/etienne-nichols-10705174/MedTech 101: The Entrepreneur's MindsetIn MedTech, a startup is a new company in its early stages, often focused on a single breakthrough technology. But as Steve Bell explains, a great technical idea isn't enough; you need a great business idea. This means the company must have a clear path to profitability and market sustainability.Think of it this way: a car enthusiast might build a highly advanced, custom race car in their garage (a great technical idea). But if it costs a fortune to build and can only compete in a small, niche racing circuit with no prize money, it's not a viable business. An entrepreneur, on the other hand, would look at a market need—say, a demand for affordable, electric delivery vehicles—and then design a vehicle to meet that need, ensuring there's a clear way to make a profit. The entrepreneur focuses on the market need first, not just the technology.Feedback Call-to-ActionWhat are your biggest challenges as a MedTech entrepreneur? Email us your questions or topic suggestions at podcast@greenlight.guru. We read every message and value your input! Your feedback helps us shape future episodes and provide the most relevant content for the MedTech community.SponsorsThis episode is brought to you by Greenlight Guru. Launching a MedTech startup is a marathon, not a sprint, and managing your quality and clinical data shouldn't slow you down. Greenlight Guru offers a modern, intuitive QMS & EDC solution specifically for medical device professionals. Our software helps you streamline your product development, ensuring you can focus on building a successful business without getting bogged down by compliance issues. Greenlight Guru provides the tools you need to stay on track from concept to market and beyond.